| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -9,933,147 | -6,761,917 |
| Proceeds from issuance of common stock | 834,397 | 459,019 |
| Common stock issuance costs | 35,729 | 18,291 |
| Net cash provided by financing activities | 798,668 | 440,728 |
| Change in cash, cash equivalents and restricted cash | -9,134,479 | -6,321,189 |
| Effect of exchange rate changes on cash | 3,406 | - |
| Cash and cash equivalents at beginning of period | 22,890,055 | - |
| Cash and cash equivalents at end of period | 13,758,982 | - |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)